LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 165

Search options

  1. Article: Hyper Mucinous Proliferations in the Mucosa of Patients with Inflammatory Bowel Disease: Histological Lesions with a Real Potential for Neoplastic Evolution?

    Falco, Enrico Costantino / Ribaldone, Davide Giuseppe / Canavese, Gabriella

    Diagnostics (Basel, Switzerland)

    2024  Volume 14, Issue 5

    Abstract: Background and aims: Mucin disfunction is a critical event in the pathogenesis of inflammatory bowel disease (IBD). Although hyper mucinous conditions have a still debated implication in the clinical evolution of this disorder, hyper mucinous villous ... ...

    Abstract Background and aims: Mucin disfunction is a critical event in the pathogenesis of inflammatory bowel disease (IBD). Although hyper mucinous conditions have a still debated implication in the clinical evolution of this disorder, hyper mucinous villous proliferations were found to have a preneoplastic biologic potential. We studied morphologic and immunophenotypic characteristics of these lesions in ileocolonic resections for IBD to add evidence about the evolutive potential of these lesions in samples with well oriented wall structures.
    Methods: Morphologic characteristics of bowel samples from 20 patients resected for IBD and with raised lesions at gross examination were studied and sections from cases with hyper mucinous lesions were stained with the following antibodies: Ki 67, p21, and p27, which were employed to evaluate the characteristics of the proliferative and differentiative activity of the epithelial structures; mismatch repair proteins and p53 have been studied as proteins implicated in carcinogenesis in IBD-affected mucosa; mucins subtypes in hyper mucinous structures were evaluated with MUC-2 and MUC-6. The results in 11 cases of saplings were that they harbored hyper mucinous proliferations. The occurrence of hyper mucinous structures was not related to dysplastic lesions, pseudo pyloric metaplasia, subtype of disease, or activity. In only one of our cases, mild cytologic atypia in the proliferative compartment was detected. Proliferation markers (Ki 67, p53) were expressed in the proliferative compartments of mucosal crypts and antiproliferative proteins p21 and p27 were expressed in differentiated epithelium. MMR proteins expression was limited to the proliferative compartment of the hyper mucinous projections. Mucin subtypes distribution was regular in the epithelium of hyper mucinous proliferations.
    Conclusions: The present monocentric retrospective study was conducted on surgical samplings with well oriented crypts. Collected data show that hyper mucinous features are frequent occurrences in raised lesions in IBD patients. In hyper mucinous proliferations of the selected cases, the status of the proliferative cycle, the expression of the proteins most frequently involved in carcinogenetic pathways of mucosa affected by IBD, and the mucins subtypes expression have no evident anomalies. Findings are not consistent with the increased risk of neoplastic evolution observed in other studies; rather, they suggest a hyperplastic nature. However, the capacity of hyper mucinous raised lesions for neoplastic evolution should be ruled out with more extensive prospective studies to identify functional defects that could explain the hypothesized neoplastic potential.
    Language English
    Publishing date 2024-02-26
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662336-5
    ISSN 2075-4418
    ISSN 2075-4418
    DOI 10.3390/diagnostics14050499
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Special Issue "Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice".

    Caviglia, Gian Paolo / Ribaldone, Davide Giuseppe

    Journal of clinical medicine

    2022  Volume 11, Issue 10

    Abstract: It is an exciting time for gastroenterology and hepatology [ ... ]. ...

    Abstract It is an exciting time for gastroenterology and hepatology [...].
    Language English
    Publishing date 2022-05-16
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm11102797
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Is a Protective Stoma Mandatory in Anti-Tumor Necrosis Factor-Treated Crohn's Disease Patients Undergoing Surgery?

    Resegotti, Andrea / Ribaldone, Davide Giuseppe

    Gastroenterology

    2022  Volume 164, Issue 2, Page(s) 307

    MeSH term(s) Humans ; Crohn Disease/diagnosis ; Crohn Disease/drug therapy ; Crohn Disease/surgery ; Surgical Stomas/adverse effects ; Tumor Necrosis Factor-alpha ; Necrosis/pathology
    Chemical Substances Tumor Necrosis Factor-alpha
    Language English
    Publishing date 2022-04-30
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2022.04.046
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?

    Sacco, Marco / Ribaldone, Davide Giuseppe / Saracco, Giorgio Maria

    Viruses

    2023  Volume 15, Issue 12

    Abstract: Background: Patients with chronic hepatitis C (CHC) and concomitant type 2 diabetes mellitus (DM) show a higher risk of developing hepatocellular carcinoma (HCC). Successful antiviral therapy has reduced the incidence of post-therapy HCC, but the ... ...

    Abstract Background: Patients with chronic hepatitis C (CHC) and concomitant type 2 diabetes mellitus (DM) show a higher risk of developing hepatocellular carcinoma (HCC). Successful antiviral therapy has reduced the incidence of post-therapy HCC, but the presence of DM still represents an unfavourable predictive factor even in cured patients. Metformin (MET) is recommended as a first-line therapy for DM, and its use is associated with a significant reduction in HCC among diabetic patients with chronic liver disease of different etiology, but very few studies specifically address this issue in patients with CHC.
    Aim: the aim of this review is to evaluate whether the use of MET induces a significant decrease in HCC in diabetic patients with CHC, treated or untreated with antiviral therapy.
    Methods: A search of PubMed, Medline, Web of Sciences and Embase was conducted for publications evaluating the role of MET in reducing the risk of HCC in patients with DM and CHC, with no language and study type restrictions up to 30 June 2023. Only studies fulfilling the following inclusion criteria were considered: (1) data on the incidence of HCC in the follow-up of diabetic patients with CHC only; (2) follow-up ≥24 months; (3) sufficient data to establish the rate of diabetic patients with CHC treated with metformin or other antidiabetic medications; and (4) data on the type of antiviral treatment and the clinical outcome.
    Results: Three studies met the inclusion criteria. A prospective cohort study considering only patients with DM and untreated advanced CHC, or non-responders to interferon (IFN) therapy, showed that the use of MET was associated with a significant decrease in HCC incidence, liver-related death and liver transplants. A recent retrospective study focusing on a large-scale nationwide cohort of patients with CHC in Taiwan successfully treated with IFN-based therapy stratified patients into 3 groups: non-MET users, MET users and non-diabetic patients, with 5-year cumulative rates of HCC of 10.9%, 2.6% and 3.0%, respectively, showing a significantly higher HCC risk in non-MET users compared with MET users and with non-diabetic patients, while it was not significantly different between MET users and non-diabetic patients. In a recent Italian cohort study focusing on 7007 patients with CHC treated and cured with direct-acting antiviral agents (DAAs), a combined effect of DM and MET therapy was found, showing a higher incidence of HCC in diabetic patients not taking MET compared with those without DM and those with DM taking MET.
    Conclusion: according to the current evidence, the use of MET should be encouraged in diabetic patients with CHC in order to reduce the risk of HCC; however, a well-designed randomized controlled trial is needed to establish the generalizability of the beneficial effects of MET in this particular subset of patients.
    MeSH term(s) Humans ; Carcinoma, Hepatocellular/epidemiology ; Carcinoma, Hepatocellular/etiology ; Carcinoma, Hepatocellular/prevention & control ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/epidemiology ; Antiviral Agents/therapeutic use ; Liver Neoplasms/epidemiology ; Liver Neoplasms/etiology ; Liver Neoplasms/prevention & control ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Cohort Studies ; Metformin/therapeutic use ; Prospective Studies ; Risk Reduction Behavior
    Chemical Substances Antiviral Agents ; Metformin (9100L32L2N)
    Language English
    Publishing date 2023-12-17
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v15122451
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Indication to Colectomy in the Hands of the Academic Gastroenterologist Versus the Surgeon: Old Giant Combat While Modern "Precision Medicine" Is Timidly Waving Hand to Offer Possible Help.

    Actis, Giovanni Clemente / Pellicano, Rinaldo / Ribaldone, Davide Giuseppe

    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology

    2023  Volume 34, Issue 4, Page(s) 433–434

    MeSH term(s) Humans ; Gastroenterologists ; Colectomy ; Surgeons ; Laparoscopy
    Language English
    Publishing date 2023-03-17
    Publishing country Turkey
    Document type Journal Article
    ZDB-ID 1340275-4
    ISSN 2148-5607 ; 1300-4948
    ISSN (online) 2148-5607
    ISSN 1300-4948
    DOI 10.5152/tjg.2023.22567
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Roux-en-Y Gastric Bypass and Celiac Disease : Gastric Bypass and Celiac Disease.

    Ribaldone, Davide Giuseppe

    Obesity surgery

    2018  Volume 28, Issue 11, Page(s) 3638

    MeSH term(s) Celiac Disease ; Gastric Bypass ; Humans ; Obesity, Morbid/surgery ; Postoperative Complications ; Weight Loss
    Language English
    Publishing date 2018-08-24
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1070827-3
    ISSN 1708-0428 ; 0960-8923
    ISSN (online) 1708-0428
    ISSN 0960-8923
    DOI 10.1007/s11695-018-3477-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: ACG Clinical Guideline on Crohn's Disease: A Point of View from Europe.

    Ribaldone, Davide Giuseppe

    The American journal of gastroenterology

    2018  Volume 114, Issue 5, Page(s) 826

    MeSH term(s) Adult ; Crohn Disease ; Europe ; Humans
    Language English
    Publishing date 2018-11-08
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 390122-1
    ISSN 1572-0241 ; 0002-9270
    ISSN (online) 1572-0241
    ISSN 0002-9270
    DOI 10.1038/s41395-018-0410-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Bariatric Surgery and Inflammatory Bowel Disease: a Role for Microbiota?

    Ribaldone, Davide Giuseppe / Pellicano, Rinaldo

    Obesity surgery

    2020  Volume 30, Issue 3, Page(s) 1143–1144

    MeSH term(s) Bariatric Surgery ; Humans ; Inflammatory Bowel Diseases/surgery ; Microbiota ; Obesity, Morbid/surgery
    Language English
    Publishing date 2020-01-07
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1070827-3
    ISSN 1708-0428 ; 0960-8923
    ISSN (online) 1708-0428
    ISSN 0960-8923
    DOI 10.1007/s11695-020-04401-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis.

    Bezzio, Cristina / Vernero, Marta / Ribaldone, Davide Giuseppe / Alimenti, Eleonora / Manes, Gianpiero / Saibeni, Simone

    Cancers

    2023  Volume 15, Issue 8

    Abstract: Tofacitinib is approved for several immune-mediated inflammatory diseases, but safety concerns have recently been raised. We searched PubMed (accessed on 27 February 2023) for original articles regarding tofacitinib's cancer risk when used for rheumatoid ...

    Abstract Tofacitinib is approved for several immune-mediated inflammatory diseases, but safety concerns have recently been raised. We searched PubMed (accessed on 27 February 2023) for original articles regarding tofacitinib's cancer risk when used for rheumatoid arthritis, ulcerative colitis, Crohn's disease, psoriatic arthritis, and ankylosing spondylitis. Of the 2047 initial records, 22 articles describing 26 controlled studies (including 22 randomized controlled trials) were selected. In the comparison between tofacitinib and any control treatment, the relative risk (RR) for any cancer was 1.06 (95% CI, 0.86-1.31;
    Language English
    Publishing date 2023-04-07
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15082197
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Fecal and Circulating Biomarkers for the Non-Invasive Assessment of Intestinal Permeability.

    Perez-Diaz-Del-Campo, Nuria / Castelnuovo, Gabriele / Ribaldone, Davide Giuseppe / Caviglia, Gian Paolo

    Diagnostics (Basel, Switzerland)

    2023  Volume 13, Issue 11

    Abstract: The study of intestinal permeability is gaining growing interest due to its relevance in the onset and progression of several gastrointestinal and non-gastrointestinal diseases. Though the involvement of impaired intestinal permeability in the ... ...

    Abstract The study of intestinal permeability is gaining growing interest due to its relevance in the onset and progression of several gastrointestinal and non-gastrointestinal diseases. Though the involvement of impaired intestinal permeability in the pathophysiology of such diseases is recognized, there is currently a need to identify non-invasive biomarkers or tools that are able to accurately detect alterations in intestinal barrier integrity. On the one hand, promising results have been reported for novel in vivo methods based on paracellular probes, i.e., methods that can directly assess paracellular permeability and, on the other hand, on fecal and circulating biomarkers able to indirectly assess epithelial barrier integrity and functionality. In this review, we aimed to summarize the current knowledge on the intestinal barrier and epithelial transport pathways and to provide an overview of the methods already available or currently under investigation for the measurement of intestinal permeability.
    Language English
    Publishing date 2023-06-05
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662336-5
    ISSN 2075-4418
    ISSN 2075-4418
    DOI 10.3390/diagnostics13111976
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top